Announcement
Immorta Bio's AI-designed SenoMune-0257 peptide aims to target senescent cells
Immorta Bio says the nine-amino-acid peptide stimulates cytotoxic T cells; first human evaluation was planned by the end of 2026.
TLDR
Immorta Bio says its AI-designed, nine-amino-acid synthetic peptide could stimulate cytotoxic T cells to clear senescent cells, which can accumulate with age and contribute to inflammation. The company planned its first human evaluation by the end of 2026; the results described so far were preclinical.
Combined views
76.5K
3 Sources, first seen ago